ArticleJournal of the American Heart Association2025
Associations of Sarcopenia and Its Components With Cardiovascular Risk: Five-Year Longitudinal Evidence From China Health and Retirement Longitudinal Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Differential impact of cumulative cerebral small-vessel disease burden on ischemic versus hemorrhagic stroke recurrence in hemorrhage-prone patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Trial
- Interrelationship Between Sarcopenia, Frailty and Cardiovascular Disease-The Crucial Role of Obesity in Hypothesis Generation-A Narrative Review.Journal of personalized medicine · 2026Review
- Musculoskeletal degeneration and cardiovascular aging: a narrative review of shared mechanobiological pathways.Molecular biology reports · 2026Review
- Associations between sarcopenic obesity and the risk of cardiovascular-kidney-metabolic syndrome progression: insights from the China health and retirement longitudinal study.Diabetology & metabolic syndrome · 2025Article
- Unraveling the metabolic pathways between atherosclerosis and sarcopenia.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia, an age-related condition, has an unclear association with cardiovascular disease (CVD) risk. We aimed to analyze whether sarcopenia and its individual components are associated with new-onset CVD in middle-aged and older adults. METHODS AND
resultsData were derived from the China Health and Retirement Longitudinal Study, with sarcopenia defined by the Asian Working Group for Sarcopenia 2019 criteria. The primary outcome was composite CVD, comprising heart disease and stroke. Multivariable Cox proportional hazards regression analysis and Fine-Gray subdistribution hazards models were used to calculate hazard ratios (HRs), subdistribution hazard ratios (SHRs), and 95% CIs. A total of 10 649 participants (mean age 64.5±10.7 years, 47.6% male) were included. During mean follow-up of 4.60±1.06 years, there were 1649 (15.5%) cases of new-onset CVD. Possible sarcopenia was linked to increased new-onset composite CVD risk (HR, 1.21 [95% CI, 1.06-1.37]; SHR, 1.20 [95% CI, 1.05-1.35]), whereas sarcopenia and severe sarcopenia showed no association. Restricted cubic spline analysis revealed that 5-time chair stand test (5-CST) was associated with new-onset composite CVD, with significant sex-specific interaction (
conclusionPossible sarcopenia was associated with increased risk of new-onset composite CVD, suggesting that progression to definite sarcopenia may not parallel cardiovascular risk. Longer 5-CST was linked to higher risk of new-onset composite CVD, with sex-specific association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.